Enanta Pharmaceuticals (ENTA) Scheduled to Post Quarterly Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA) is set to issue its quarterly earnings data after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($1.26) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. The firm had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Price Performance

Shares of Enanta Pharmaceuticals stock opened at $15.17 on Friday. Enanta Pharmaceuticals has a 52 week low of $8.08 and a 52 week high of $37.14. The stock has a 50 day moving average price of $14.92 and a two-hundred day moving average price of $12.00.

Analysts Set New Price Targets

Several analysts recently issued reports on ENTA shares. JPMorgan Chase & Co. reduced their price target on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a research report on Thursday, February 8th. StockNews.com lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, April 6th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $19.33.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.